Pre-seed open · 12 months to first market AVIX Pharmaceuticals Limited · United Kingdom & Bangladesh
Roadmap

Twelve months to first sale. Four years to a moat.

Two regulatory routes with very different timescales, run deliberately in parallel so the fast one funds and de-risks the slow one.

Timeline of quarterly milestones from patent filing to first commercial sale
01 ·The next twelve months

Quarter by quarter.

Every item is fundable, measurable and dated. Nothing here depends on an approval we do not control.

Q1 · Intellectual property

Priority patent applications filed on lead combinations

The first use of funds. Until priority applications exist the combinations are unprotected and the company is hard to value. Filing also unlocks the scientific disclosure needed for partnership discussions.

Q1 · Laboratory

MIC panel across an expanded isolate set; serial-passage protocol agreed

Converts screening data into the characterisation data regulators and partners recognise. Serial passage answers the central scientific question: does resistance develop more slowly against a three-target combination?

Q2 · Regulatory

Classification confirmed with advisers in Bangladesh, UK and EU

Determines dossier scope and what may lawfully be claimed in each market. Whether the product is a feed material, a zootechnical additive or a veterinary medicine changes cost, timeline and value materially.

Q2–Q3 · In-vivo

Controlled broiler study: efficacy, feed conversion, mortality, safety, residues

The single result that determines whether this becomes a product. Designed to EFSA data standards so the same study serves both regulatory tracks rather than being repeated later at full cost.

Q3 · Manufacture

CMO batches produced; potency assay and stability programme running

Batch-to-batch consistency is this category's documented failure mode. Botanical potency varies with growing conditions, harvest and extraction, so a validated potency assay is a competitive asset in itself.

Q3–Q4 · Commercial

Distribution agreement signed in beachhead market

Converts a laboratory result into a route to a customer.

Q4 · Commercial

First commercial sales on Track A

Revenue, field data, and proof that producers will pay — the three things that change the terms of the next round.

Q4 · Team

Animal-health regulatory and commercial hire

The capability the founding team does not currently have, recruited once there is data worth commercialising.

02 ·Regulatory reality

Why the twelve-month plan is not a European launch plan.

The programme uses two coordinated tracks rather than pretending one regulatory route fits every market.

  • Europe takes longer: full safety, efficacy and characterisation are required.23
  • Track A: lawful regional entry without therapeutic claims.
  • Track B: European evidence is built in parallel.
  • One architecture: design studies once to the higher standard.
Programme-design target

Build once. Reuse evidence wherever regulators permit.

  • Classify early · settle classification and claims before pivotal studies.
  • Design once · build analytical and stability packages to one standard.23
  • Run in parallel · coordinate safety, efficacy and regulatory work.
  • Reuse evidence · design poultry data for regional and later EU use.

Programme target: reduce duplicated studies. This is not a guaranteed regulatory timetable.

Scientific references1 source used on this page
23

European Food Safety Authority.

European Food Safety Authority. Feed additives application procedure, reviewed May 2026. The application lifecycle covers pre-submission, submission and completeness, risk assessment and post-adoption; dossiers address identity, characterisation, conditions of use, target-animal safety, consumer, user and environmental safety, and efficacy. efsa.europa.eu

The people behind the plan

Execution depends on drug-discovery judgement as much as milestones.

Meet the scientists and wider team building the programme.